This website is not associated with Arrowhead Research Corporation or Ablaris Therapeutics Inc
Prohibitin-Targeting Peptide 1 is a peptide developed at M.D. Anderson that has been shown in animal studies to cause targeted fat loss in users of the peptide, without any additional exercise. It is currently years away from being brought to the market as an approved drug. So far, clinical trials suggest that there could be minor liver damage in patients who take Prohibitin-Targeting Peptide 1, damage that can be reversed by stopping intake of the drug. However, this damage is minimal and occurred at stronger than therapeutic doses.
An Prohibitin-Targeting Peptide 1 is a sequence of amino acids that researchers hope will target and kill the fat cells in our body, by eliminating the blood supply to them. It would essentially be the weight loss miracle drug and the only drug ever approved for weight loss that kills fat cells directly. If approved by the FDA, Prohibitin-Targeting Peptide 1 will be the most succesful weight loss drug ever to come to market.
Prohibitin-Targeting Peptide 1 is a weight loss peptide currently being developed as a weight loss drug. However, currently you cannot buy Prohibitin-Targeting Peptide 1 on the market. So far, clinical trials suggest that there could be minor liver damage in patients who take Prohibitin-Targeting Peptide 1, damage that can be reversed by stopping intake of the drug. However, this damage is minimal and occurred at stronger than therapeutic doses.
With this drug, patients will be able to lose weight through a regiment of daily Prohibitin-Targeting Peptide 1 doses. Exercise would not be required for weight loss with this drug; exercise would only be required to maintain the level of weight loss once the patient is taken off Prohibitin-Targeting Peptide 1. This is a perfect drug for individuals with medical conditions that have prevented weight loss, who now wish to lose weight permanently. We truly wish that the FDA will approve Prohibitin-Targeting Peptide 1 after all clinical trials have been conducted and Prohibitin-Targeting Peptide 1 is proved to be an effective weight loss drug with minimal side effects in comparison to the debilitating disease of obesity. This website will be dedicated to posting the most up to date research and news related to Prohibitin-Targeting Peptide 1, "the miracle weight loss drug" (as quoted by the media).
- 1/04/2012 The FDA has approved a Phase I clinical trial for Prohibitin-Targeting Peptide 1!
- 06/25/2012 A study has been published showing that Prohibitin-Targeting Peptide 1 causes fat loss in mice. The study hypothesizes that the peptide will extensively help to treat diabetes.
- 07/11/2012 Phase 1 clinical trial of Prohibitin-Targeting Peptide 1 has begun!
A trademark was filed for the name adipotide™ on December 16, 2011 for uses in the medical industry. Adipotide.com was registered on November 9, 2011 to provide information on what I then thought was the generic name for Prohibitin-Targeting Peptide 1. At the time of the domain's registration there was no reference in the journal study to adipotide™ being or intending to be a trademark, rather it was being referenced more like the actual name of a compound, not a brand name. As a result this website will provide information on the development of adipotide™ only and no form of advertisements will be accepted for display. The trademark adipotide™ is the property of its respective owners.